Taro Pharma (TARO) Tops Q1 EPS by 9c

Taro Pharma (NYSE: TARO) reported Q1 EPS of $0.40, $0.09 better than the analyst estimate of $0.31. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $156.06 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04